Table 2. Long-Term Secondary Outcomes.
| Characteristic or treatment | Time of outcome, y | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Locoregional recurrence | Locoregional failure | Distant recurrence | Disease-free survival | Overall survival | ||||||
| 3 | 5 | 3 | 5 | 3 | 5 | 3 | 5 | 3 | 5 | |
| Studies, No. | 11 | 7 | 10 | 6 | 8 | 5 | 13 | 7 | 11 | 8 |
| Participants, No. | 5749 | 4886 | 5234 | 5234 | 4811 | 3016 | 7409 | 5302 | 5576 | 5625 |
| τ2 | 0 | 0 | 0 | NA | 0 | 0 | 0 | 0 | 0.002 | 0.005 |
| Consistency | ||||||||||
| CnG, Cochran Q; df | 0.88; 3 | NA | 0.44; 2 | NA | 0.24; 1 | NA | 0.66; 3 | NA | 2.06; 3 | NA |
| P value | .83 | NA | .80 | NA | .62 | NA | .88 | NA | .56 | NA |
| CnL, comparisons, No./total No.a | 0/8 | NA | 0/6 | NA | 0/3 | NA | 0/8 | NA | 0/8 | NA |
| Comparison vs L-CRT1, RR (95% CI) | ||||||||||
| L-CRT + consolidation | 0.59 (0.25-1.25) | NA | 0.41 (0.22-0.78)b | NA | 0.68 (0.38-1.23) | NA | 1.15 (0.99-1.33) | NA | 1.08 (0.96-1.21) | NA |
| S-RT + consolidation | 1.08 (0.76-1.53) | 1.65 (1.03-2.63)b | 1.04 (0.74-1.45) | 1.43 (0.96-2.15) | 0.83 (0.71-0.98)b | 0.76 (0.61-0.95)b | 1.08 (1.01-1.14)b | 1.10 (1.00-1.20)b | 1.07 (1.01-1.14)b | 1.02 (0.97-1.19) |
| Induction + L-CRT | 0.76 (0.37-1.54) | 2.10 (0.22-19.99) | 0.48 (0.27-0.87)b | 2.70 (0.55-13.35) | 0.76 (0.55-1.05) | 0.98 (0.48-2.03) | 1.12 (1.01-1.24)b | 0.98 (0.74-1.30) | 1.06 (0.97-1.16) | 0.96 (0.75-1.24) |
| L-CRT2 | 0.67 (0.49-0.93)b | 0.77 (0.55-1.08) | 0.72 (0.53-0.98)b | 0.85 (0.52-1.38) | 0.80 (0.69-0.93)b | 0.92 (0.77-1.09) | 1.05 (1.01-1.08)b | 1.02 (0.97-1.08) | 1.00 (0.95-1.05) | 1.04 (0.95-1.14) |
| CHT | 0.96 (0.46-2.00) | 1.13 (0.47-2.72) | 1.05 (0.60-1.84) | 1.07 (0.51-2.23) | NA | NA | 1.00 (0.89-1.12) | 1.03 (0.97-1.09) | 1.01 (0.92-1.11) | 0.99 (0.86-1.15) |
| S-RTdelayed | NA | NA | NA | NA | NA | NA | 0.79 (0.62-0.99)b | NA | 0.94 (0.78-1.12) | NA |
| L-RT | NA | 2.08 (1.34-3.22)b | NA | 1.70 (1.22-2.36)b | NA | NA | NA | 0.93 (0.83-1.06) | NA | 1.01 (0.85-1.19) |
| S-RTearly | 1.72 (0.70-4.27) | 1.34 (0.58-3.10) | 1.72 (0.70-4.27) | 1.34 (0.58-3.10) | NA | 0.92 (0.65-1.30) | NA | NA | NA | 1.07 (0.88-1.30) |
Abbreviations: CHT, chemotherapy; CnG, consistency–global test; CnL, consistency–local test; induction + L-CRT, induction CHT plus consolidation long-course chemoradiotherapy; L-CRT + consolidation, L-CRT plus consolidation CHT; L-CRT1, L-CRT with single-agent fluoropyrimidine-based CHT; L-CRT2, L-CRT with duplex CHT drug (fluoropyrimidine plus oxaliplatin); L-RT, long-course radiotherapy; NA, not available; RR, relative risk; S-RT + consolidation, short-course RT plus consolidation CHT; S-RTdelayed, S-RT plus delayed rectal resection; S-RTearly, S-RT plus early rectal resection.
The denominator is the total number of comparisons included in the analysis; the numerator is the number of inconsistencies between direct and indirect estimates.
Significant RR (95% CI).